摘要
目的评价微卡(母牛分枝杆菌菌苗)作为免疫调节剂辅助治疗复治涂阳肺结核的疗效。方法将80例复治涂阳肺结核病人随机分为治疗组40例及对照组40例,两组化疗方案相同3SHRZE/6HR,治疗组肌肉注射微卡,每半月1次,共9个月,观察药物不良反应。结果疗程结束时,治疗组痰菌阴转率为92.5%,明显高于对照组77.5%(P<0.01);治疗组病灶吸收,空洞关闭率分别为97.5%和91.7%均明显高于对照组85.0%和78.3%(P<0.01),有统计学意义。结论微卡是一种新型免疫调节剂,可提高复治涂阳肺结核的疗效,值得推广。
Objective To evaluate the therapeutic effect of Mycobacterium vaccine on re-treated smear positive pulmonary tuberculosis. Methods Eighty cases of re-treated smear positive pulmonary tuberculosis were divided randomly into study group （40 cases） and control group （40 cases）. The two groups were treated by chemotherapy with a regimen of 3SHRZE/6HR. And the study group was given intramuscular injections of Mycobacterium vaccine once every half-month for nine months. Results At the end of treatment, the sputum negative conversion rate of treatment group was 92. 5%, while the rate of control group was 77. 5% （P 〈0.01 ） ;The foci absorption rate and the cavity closing rate of the treatment group were 97.5% and 91.7% respectively, while the rates of control group were 85.0% and 78.3% ： P 〈0.01. Conclusion Mycobacterium vaccine is a new immunity injection. It can improve the therapeutic effect of re - treated smear positive pulmonary tuberculosis. It is worth recommending.
出处
《临床肺科杂志》
2008年第2期142-143,共2页
Journal of Clinical Pulmonary Medicine
关键词
结核
肺/药物疗法
微卡
tuberculosis
pulmonary/drug therapy
mycobacterium vaccine
